Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ProTrans
- Development stage
- Phase 2
- Lead developer
- NextCell Pharma
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
ProTrans is an advanced therapy medicinal product (ATMP) consisting of allogeneic mesenchymal stem cells (MSCs) derived from the umbilical cord of healthy donors. Developed by NextCell Pharma, it is primarily investigated for the treatment of Type 1 Diabetes (T1D) and other inflammatory conditions. The therapy utilizes a proprietary selection algorithm to identify donors whose cells exhibit high immunomodulatory potency. ProTrans functions by modulating the patient's immune system to suppress the autoimmune attack on pancreatic beta cells, thereby preserving endogenous insulin production as measured by C-peptide levels. It is administered via intravenous infusion and has demonstrated a favorable safety profile in clinical trials, with evidence of efficacy in slowing disease progression in recently diagnosed T1D patients.
- Brand names
- ProTrans
- Other names
- Umbilical cord-derived mesenchymal stem cellsUC-MSCs
Beyond the preview
Go deeper on ProTrans.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ProTrans.